Clearside Biomedical CMO Thomas Ciulla resigns, becomes advisor under consulting agreement

Clearside Biomedical, Inc.

Thomas Ciulla resigned as CMO and CDO effective Feb 17, 2023; will serve as Chairman of Scientific Advisory Board and Chief Medical Advisor – Retina.
Consulting fee of $8,000 per month; initial term one year, renewable at Company's option.
Stock options continue vesting through Aug 31, 2023 (Jan 4, 2023 option through Jan 4, 2024); RSU vesting ceased on Feb 17, 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Thomas Ciulla

Chief Medical Officer and Chief Development Officer

CLSDQ · Clearside Biomedical, Inc.

Effective: 2023-02-17
Filed: February 21, 2023, 6:59 PM ET

Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Ciulla resigned as Chief Medical Officer and Chief Development Officer at Clearside Biomedical, Inc..

Action: resigned
Role: Chief Medical Officer and Chief Development Officer

Exact text from the filing

Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17, 2023

View on SEC.gov

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-003293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.